ForSight Robotics, a YOKNEAM, Israel based- the pioneer in ophthalmic robotic surgery was announced completed a $55 million Series A round to advance the world’s first surgical platform for fully robotic cataract surgery: ORYOM.
The Adani Group was led the funding round alongside existing investors Eclipse Ventures and Mithril Capital.
A number of new investors, including Provenio Capital, Precision Capital, Reiya Ventures, the Ljungstrom family office, and other prominent private investors also joined the round.
The funding will be used to accelerate the development of the ForSight's ORYOM platform in clinical trials.
Company: ForSight Robotics LTD.
Raised: $55.0 M
Round: Series A
Funding Month: July 2022
Lead Investors: Adani Group
Additional Investors: Eclipse Ventures and Mithril Capital, Provenio Capital, Precision Capital, and Reiya Ventures
Company Website: https://www.forsightrobotics.com/
Software Category: Ophthalmic Robotic Surgery
About the Company: ForSight was founded in 2020 by Professor Moshe Shoham, who serves as its chief scientist and previously founded Mazor Robotics Ltd., which was acquired by Medtronic in December 2018 in a $1.6 billion deal. Shoham co-founded the company with Dr. Daniel Glozman (CEO) and Joseph Nathan (CBO). ForSight’s flagship robotic platform will increase accessibility to ophthalmic surgery procedures worldwide and ultimately transform the future of eye surgery. The company currently employs 30 people out of its offices in Yokneam. ForSight plans to bridge the worldwide gap in the accessibility to eye surgery, and help over one billion people who suffer from preventable vision impairment and eye diseases. ForSight’s first procedure is cataract surgery, the most common surgical procedure with approximately 28 million procedures worldwide per year. According to the U.S. National Institutes of Health, there are over 25 million Americans who suffer from cataract and hundreds of millions of cataract patients around the world. The company is working on other preventable ophthalmic diseases that can benefit from the accuracy of a robotics platform and advanced visualization such as retinal diseases and glaucoma among others.